BWX Technologies shares have moved in a choppy, lower range through the fall of 2026. The stock eased from the mid-$140s to roughly $130 in a matter of weeks, reflecting profit-taking and broader valuation pressure across the nuclear and defense complex rather than any weakening in operating results. This recent softness stands in contrast to the longer-term strength of the nuclear theme, where demand tied to naval propulsion, grid decarbonization, and electricity-intensive data centers has kept investor attention elevated.
Sentiment on the name remains mixed. Several analysts reiterated constructive ratings while trimming price targets, and the consensus view still leans positive, though near-term execution and a fourth-quarter-heavy earnings profile have kept a lid on enthusiasm. The stock's move of less than 10% over the trailing 30 days leaves it within a normal trading range for a large-cap industrial. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
BWX Technologies, Inc. designs and manufactures nuclear components, fuel, and specialized services across two segments: Government Operations and Commercial Operations. In Government Operations, BWXT is the sole manufacturer of nuclear reactors and fuel for the U.S. Navy's submarine and aircraft-carrier fleets, while also handling national security materials, uranium processing, and advanced and microreactor programs. In Commercial Operations, the company supplies steam generators, reactor components, fuel, and field services for commercial nuclear plants, including CANDU reactors, and serves the nuclear medicine market.
The company's competitive moat rests on unique regulatory licenses, security clearances, and highly specialized manufacturing infrastructure that are difficult to replicate. BWXT describes itself as the only large commercial nuclear equipment manufacturer in North America. That positioning, combined with a multi-year backlog concentrated in long-cycle naval propulsion work, gives the company significant revenue visibility and pricing power relative to many industrial peers. Investors follow the stock closely as a bellwether for both U.S. defense spending and the revival of commercial nuclear power.
The most consequential recent development was BWXT's decision to raise its 2026 financial guidance following second-quarter results. Revenue of $901.6 million rose 18% year over year, while Commercial Operations revenue climbed roughly 72%, including about 33% organic growth. The company also lifted its full-year free cash flow outlook to $345–$360 million.
Portfolio activity reshaped the business during the period. BWXT completed its acquisition of Precision Components Group in July, adding commercial nuclear manufacturing capability, and agreed to sell just over 80% of its medical business and Kinectrics stable-isotope enrichment operations to Nordic Capital in a transaction valued at up to $800 million, allowing management to focus on nuclear national security and commercial power.
Analyst activity has been mixed. Northland Securities and Jefferies issued Buy ratings in early October, while Truist Financial and Maxim Group maintained Hold ratings, and Wells Fargo reiterated a Hold with a $170 price target. Bank of America trimmed its target from $250 to $210. These revisions, alongside broader sector rotation, contributed to the recent softness in the share price even as the underlying backlog and demand signals remained strong.
BWXT's forward story centers on converting a record backlog into earnings. Management has pointed to the nuclear industry's "multi-decade super cycle," supported by naval propulsion, national security programs, and commercial reactor demand. The company expects its next quarterly earnings release around early November 2026, and consensus estimates point to revenue of roughly $992 million and EPS near $1.19, which will be closely watched for signs that execution remains on track.
Key factors to monitor include the pace of new-build nuclear equipment orders, capacity expansion decisions, and the margin trajectory in Commercial Operations, where management lowered its 2026 adjusted EBITDA margin guidance to about 13% to fund growth investments. The concentration of second-half earnings in the fourth quarter also adds execution risk. On the government side, defense budget priorities and contract award timing remain important swing factors. Broader nuclear peers such as GE Vernova and Huntington Ingalls Industries underscore how demand for nuclear equipment and naval shipbuilding continues to shape the sector's outlook. From what I see, this is important because the backlog conversion will test execution in the quarters ahead.
I have found Tickeron's AI Trading Bots helpful when tracking automated strategies across defense and nuclear stocks like BWXT. The platform surfaces top-performing bots that monitor thousands of tickers, allowing a quick comparison of different algorithmic approaches without relying on a single model. This gives a useful window into how quantitative systems are positioning in real time.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BWXT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 31 of 37 cases where BWXT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 84%.
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where BWXT advanced for three days, in 229 of 327 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Momentum Indicator moved below the 0 level on October 20, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BWXT as a result. In 42 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 48%.
The Moving Average Convergence Divergence Histogram (MACD) for BWXT turned negative on October 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 23 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 49%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BWXT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 58%.
The Aroon Indicator for BWXT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron SMR rating for this company is 35 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 59 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. BWXT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.733) is normal, around the industry mean (4.788). P/E Ratio (32.866) is within average values for comparable stocks, (16.638). BWXT's Projected Growth (PEG Ratio) (27.780) is very high in comparison to the industry average of (2.564). Dividend Yield (0.008) settles around the average of (0.060) among similar stocks. P/S Ratio (3.811) is also within normal values, averaging (18.330).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of components and services to nuclear power industry
Industry AerospaceDefense